01—Abstract
Summary
Summary of the 8-K filed February 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Broadridge Financial Solutions, Inc. (BR) filed this Form 8-K on February 10, 2025 under Item 7.01 (Regulation FD Disclosure) to furnish its February 2025 investor presentation, posted that day to its website at broadridge-ir.com and attached as Exhibit 99.1.
The information is furnished rather than filed, so it is not subject to Section 18 liability. The filing itself contains no new financial results; the substance lies in the presentation, which reaffirms fiscal year 2025 guidance from the January 31, 2025 earnings call. The presentation states that Broadridge had $4.2 billiona of FY'24 recurring revenue and sets objectives for FY'24-26 of 7-9% recurring revenue growth (5-8% organic) and 8-12% adjusted EPS growth.
FY'25 guidance calls for 6-8% recurring revenue growth in constant currency, adjusted operating income margin of about 20%, adjusted EPS growth of 8-12%, and closed sales of $290b-$330 million. The company reported FY'24 total revenue of $6.5 billion, GAAP diluted EPS of $5.86, and adjusted EPS of $7.73, and it cites a FY'25 annual dividend of $3.52 per share, subject to board declaration. For the fiscal second quarter ended December 31, 2024, the presentation reports recurring revenues of $980 million (up 9%), total revenues of $1,589 million (up 13%), GAAP diluted EPS of $1.20 (up 103%), and adjusted EPS of $1.56 (up 70%).
Closed sales declined to $46 millionc from $58 million, a 21% decrease. The presentation also states that free cash flow for the six months ended December 31, 2024 was $56.3 million, compared with $91.4 million a year earlier.
02—Key points
Key Highlights
- Filing type: Item 7.01 Regulation FD disclosure furnishing the February 2025 investor presentation (Exhibit 99.1); the material is furnished, not filed, under Section 18 of the Exchange Act.
- Fiscal Q2 2025 (three months ended December 31, 2024): recurring revenues $980 million (up 9% in constant currency), total revenues $1,589 million (up 13%), and adjusted operating income margin of 16.6% (up 420 bps).
- Q2 adjusted EPS of $1.56 versus $0.92 a year earlier (up 70%); GAAP diluted EPS of $1.20 versus $0.59.
- Closed sales were $46 million in Q2 FY25, down 21% from $58 million, a key leading indicator for recurring revenue growth.
- FY'25 guidance reaffirmed: recurring revenue growth of 6-8% (constant currency), adjusted operating income margin of about 20%, adjusted EPS growth of 8-12%, and closed sales of $290-$330 million.
- Three-year FY'24-26 objectives: 7-9% recurring revenue growth, 8-12% adjusted EPS growth, and 50+ bps annual adjusted operating income margin expansion; FY'25 dividend of $3.52 per share is subject to board approval.
- Free cash flow for the six months ended December 31, 2024 was $56.3 million, down from $91.4 million; FY'24 free cash flow was $943.2 million.
03—Questions
Frequently Asked Questions
Does this 8-K disclose new financial results?
No. The filing furnishes the February 2025 investor presentation, which includes fiscal Q2 2025 results and reaffirms FY'25 guidance that was first given on the January 31, 2025 earnings call.
What growth targets does Broadridge set for FY'24-26?
The presentation sets a 7-9% recurring revenue growth objective (5-8% organic), an 8-12% adjusted EPS growth objective, and annual adjusted operating income margin expansion of 50+ bps.
What is the FY'25 guidance?
Recurring revenue growth of 6-8% in constant currency, adjusted operating income margin of about 20%, adjusted EPS growth of 8-12%, and closed sales of $290-$330 million, all unchanged from the January 31, 2025 earnings call.
Why did closed sales decline in the second quarter?
The presentation shows Q2 FY25 closed sales of $46 million versus $58 million in Q2 FY24, a 21% decrease. The filing does not explain the cause.
What is the dividend outlook?
The presentation cites a FY'25 annual dividend amount of $3.52 per share, compared with $3.20 for FY'24, and notes that the amount is subject to Board declaration.
04—Continue